Ensysce Biosciences Issues Annual Shareholder Letter
~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for...
~ FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for...
Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & DevelopmentBASEL, Switzerland,...
BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Software upgrade advances complete workflow solutions New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X,...
New claims-sourced RADAR models demonstrate positive predictive value BOSTON, Jan. 7, 2025 /PRNewswire/ -- Together Senior Health (Together), a Linus Health...
The Keynote Address, entitled "Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD," will be presented at 10:30AM PT...
Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription...
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
IRVINE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused...
IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical...
Three Stations to Host Interactive Experiences from January 6–11 LAS VEGAS, Jan. 3, 2025 /PRNewswire/ -- Assisted Intelligence Wellness (known...
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total...
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
LAS VEGAS, Dec. 30, 2024 /PRNewswire/ -- Assisted Intelligence Wellness Inc. (AI Wellness), a global leader in integrating AI with personalized...
Black Book unveils critical insights into the global EHR landscape, spotlighting 121 local and regional vendors across 53 countries as...
SAN FRANCISCO, Dec. 19, 2024 /PRNewswire/ -- Darmiyan, Inc., a leader in brain health technology, proudly announces its participation in...
MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing...
North American drug delivery development experts added to help guide Lexaria's strategic plans KELOWNA, BC / ACCESSWIRE / December 18,...
BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS)...
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical...